Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 3	JAN 25	Annual Reload of MEDLINE database
NEWS 4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS 9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 11	APR 02	DWPI: New display format ALLSTR available
NEWS 12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 14	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 11:40:40 ON 07 JUN 2010

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 11:41:12 ON 07 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 JUN 2010  HIGHEST RN 1226953-63-4
DICTIONARY FILE UPDATES:   3 JUN 2010  HIGHEST RN 1226953-63-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s dovitinib
L1            2 DOVITINIB

=> d l1 1-2

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   692737-80-7  REGISTRY
ED   Entered STN:  14 Jun 2004
CN   Propanoic acid, 2-hydroxy-, compd. with
     4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-
     quinolinone (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Propanoic acid, 2-hydroxy-, compd. with
     4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-
     quinolinone (1:1) (9CI)
OTHER NAMES:
CN   CHIR 258
CN   Dovitinib lactate
CN   TKI 258
DR   1000873-96-0
MF   C21 H21 F N6 O . C3 H6 O3
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPATFULL

     CM   1

     CRN  405169-16-6
     CMF  C21 H21 F N6 O
```



CM 2

CRN 50-21-5
CMF C3 H6 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

68 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
69 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN
RN 405169-16-6 REGISTRY
ED Entered STN: 12 Apr 2002
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI)
OTHER NAMES:
CN 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
CN Dovitinib
DR 804551-71-1
MF C21 H21 F N6 O
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
              26 REFERENCES IN FILE CA (1907 TO DATE)
               2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              26 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    10.19      10.41

FILE 'CAPLUS' ENTERED AT 11:41:33 ON 07 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jun 2010  VOL 152 ISS 24
FILE LAST UPDATED: 6 Jun 2010  (20100606/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Apr 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1
L2          76 L1

=> s l2 and (cancer or tumor or neoplasm)
        458652 CANCER
         67289 CANCERS
        475156 CANCER
                 (CANCER OR CANCERS)
        547410 TUMOR
        196404 TUMORS
        607096 TUMOR
                 (TUMOR OR TUMORS)
          4892 TUMOUR
          1843 TUMOURS
          6616 TUMOUR
                 (TUMOUR OR TUMOURS)
        607544 TUMOR
                 (TUMOR OR TUMOUR)
        598060 NEOPLASM
         38884 NEOPLASMS
```

```
       615483 NEOPLASM
                (NEOPLASM OR NEOPLASMS)
L3          54 L2 AND (CANCER OR TUMOR OR NEOPLASM)

=> s l3 and ad<20031107
      4779868 AD<20031107
                (AD<20031107)
L4           3 L3 AND AD<20031107

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           3 DUP REM L4 (0 DUPLICATES REMOVED)

=> d l5 1-3 ibib abs hitstr

L5   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2005:1242789  CAPLUS
DOCUMENT NUMBER:          143:477969
TITLE:                    Preparation of benzimidazole quinolinones for
                          inhibiting FGFR3 and treating multiple myeloma
INVENTOR(S):              Cai, Shaopei; Chou, Joyce; Harwood, Eric; Heise, Carla
                          C.; Machajewski, Timothy D.; Ryckman, David; Shang,
                          Xiao; Wiesmann, Marion; Zhu, Shuguang
PATENT ASSIGNEE(S):       Chiron Corporation, USA
SOURCE:                   U.S. Pat. Appl. Publ., 239 pp., Cont.-in-part of U.S.
                          Ser. No. 644,055.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   7
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     US 20050261307       A1    20051124    US 2004-983174           20041105
     US 20040092535       A1    20040513    US 2003-644055           20030819 <--
     US 7470709           B2    20081230
     CN 1692112           A     20051102    CN 2003-824565           20030819 <--
     CN 100526312         C     20090812
     US 20050203101       A1    20050915    US 2004-839793           20040505
     ZA 2006003598        A     20080430    ZA 2006-3598             20060505
     US 20090281100       A1    20091112    US 2008-317493           20081223
     US 20090181979       A1    20090716    US 2009-398130           20090304
     AU 2009238373        A1    20091217    AU 2009-238373           20091120
PRIORITY APPLN. INFO.:                       US 2002-405729P     P    20020823
                                             US 2002-426107P     P    20021113
                                             US 2002-426226P     P    20021113
                                             US 2002-426282P     P    20021113
                                             US 2002-428210P     P    20021121
                                             US 2003-460327P     P    20030403
                                             US 2003-460328P     P    20030403
                                             US 2003-460493P     P    20030403
                                             US 2003-478916P     P    20030616
                                             US 2003-484048P     P    20030701
                                             US 2003-644055      A2   20030819
                                             US 2003-517915P     P    20031107
                                             US 2003-526425P     P    20031202
                                             US 2003-526426P     P    20031202
                                             US 2004-546017P     P    20040219
                                             US 2002-426204P     P    20021113
                                             US 2003-460369P     P    20030403
                                             AU 2003-290699      A3   20031112
```

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:477969
GI



I



II

AB The title compds. I [A, B, C, and D = C, N; R1-R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl; R5-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H], useful for inhibiting fibroblast growth factor receptor 3 or treating a biol. condition mediated by fibroblast growth factor receptor 3, were prepared E.g., a multi-step synthesis of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one (II), starting from 5-chloro-2-nitroaniline and 1-methylpiperazine, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The mentioned above compound II was tested in various tests and showed significant antiproliferative activity. II inhibited FGFR3 receptor phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations.

IT 405169-16-6P 692737-80-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole quinolinones for inhibiting FGFR3 and treating multiple myeloma)

RN 405169-16-6 CAPLUS

CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1223876 CAPLUS
DOCUMENT NUMBER: 143:477966
TITLE: Preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer
INVENTOR(S): Gesner, Thomas G.; Barsanti, Paul A.; Harrison, Stephen D.; Ni, Zhi-Jie; Brammeier, Nathan M.; Zhou, Yasheen; Le, Vincent P.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 249 pp., Cont.-in-part of U.S. Ser. No. 644,055.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050256157	A1	20051117	US 2005-41191		20050121	
US 20040092535	A1	20040513	US 2003-644055		20030819	<--
US 7470709	B2	20081230				
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
CN 100526312	C	20090812				
US 20050203101	A1	20050915	US 2004-839793		20040505	
US 20090281100	A1	20091112	US 2008-317493		20081223	
AU 2009238373	A1	20091217	AU 2009-238373		20091120	
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	
			US 2002-426107P	P	20021113	
			US 2002-426226P	P	20021113	
			US 2002-426282P	P	20021113	
			US 2002-428210P	P	20021121	
			US 2003-460327P	P	20030403	
			US 2003-460328P	P	20030403	
			US 2003-460493P	P	20030403	
			US 2003-478916P	P	20030616	
			US 2003-484048P	P	20030701	
			US 2003-644055	A2	20030819	
			US 2004-538984P	P	20040123	
			US 2002-426204P	P	20021113	
			US 2003-460369P	P	20030403	
			US 2003-517915P	P	20031107	
			AU 2003-290699	A3	20031112	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:477966; MARPAT 143:477966
GI



I

AB The title compds. [I; A, B, C, D = C, N; R1 = H, halo, CN, NO2, etc.; R2, R3 = H, halo, NO2, CN, etc.; R4 = H, (un)substituted alkyl; R5, R8 = H, (un)substituted alkyl, alkenyl, heterocyclyl; or R5 may be absent if A = N; or R8 may be absent if D = N; R6, R7 = H, halo, NO2, CN, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or R9 and R10 join together to form one or more rings, each having 5-7 members], useful for inhibiting checkpoint kinase 1, inducing cell cycle progression, and increasing apoptosis in cells, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The compds. I were tested against various kinases. Two of the prepared compds. I, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2-(1H)-one and 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-4-[(piperidin-

2-ylmethyl)amino]quinolin-2(1H)-one, were found to be potent inhibitors of CHK1 with IC50 of 0.32 nM and 0.63 nM, resp. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The compds. I may be used to prepare pharmaceutical compns. and may be used in conjunction with DNA damaging agents.

IT 405169-16-6P 692737-80-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer)

RN 405169-16-6 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 692737-80-7 CAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:182836 CAPLUS
DOCUMENT NUMBER: 140:235711
TITLE: Preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase
INVENTOR(S): Barsanti, Paul A.; Bussiere, Dirksen; Harrison, Stephen D.; Heise, Carla C.; Jansen, Johanna M.; Jazan, Elisa; Machajewski, Timothy D.; Mcbride, Christopher; McCrea, William R.; Ng, Simon; Ni, Zhi-Jie; Pecchi, Sabina; Pfister, Keith; Ramurthy, Savithri; Renhowe, Paul A.; Shafer, Cynthia M.; Silver, Joel B.; Wagman, Allan; Weismann, Marion
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 570 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018419	A2	20040304	WO 2003-US25990	20030819 <--
WO 2004018419	A3	20040603		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496164	A1	20040304	CA 2003-2496164	20030819 <--
AU 2003288899	A1	20040311	AU 2003-288899	20030819 <--
AU 2003288899	B2	20090903		
EP 1539754	A2	20050615	EP 2003-781286	20030819 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013743	A	20050705	BR 2003-13743	20030819 <--
CN 1692112	A	20051102	CN 2003-824565	20030819 <--
CN 100526312	C	20090812		
JP 2006503919	T	20060202	JP 2005-501762	20030819 <--
IN 2005KN00484	A	20060106	IN 2005-KN484	20050323
AU 2009238373	A1	20091217	AU 2009-238373	20091120

PRIORITY APPLN. INFO.:			
US 2002-405729P	P	20020823	
US 2002-426107P	P	20021113	
US 2002-426226P	P	20021113	
US 2002-426282P	P	20021113	
US 2002-428210P	P	20021121	
US 2003-460327P	P	20030403	
US 2003-460328P	P	20030403	

US 2003-460493P	P	20030403
US 2003-478916P	P	20030616
US 2003-484048P	P	20030701
US 2002-426204P	P	20021113
US 2003-460369P	P	20030403
WO 2003-US25990	W	20030819
US 2003-517915P	P	20031107
AU 2003-290699	A3	20031112

OTHER SOURCE(S): MARPAT 140:235711

GI



I



II

AB The title compds. [I and II; A, B, C, and D = C, N; W, X, Y and Z = C, N and at least one of W, X, Y, and Z = N; R1-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or NR9R10 = 5-7 membered ring], useful for inhibiting various enzymes and treating various conditions, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM.

IT 405169-16-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase)

RN 405169-16-6 CAPLUS
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 11:40:40 ON 07 JUN 2010)

FILE 'REGISTRY' ENTERED AT 11:41:12 ON 07 JUN 2010
L1 2 S DOVITINIB

FILE 'CAPLUS' ENTERED AT 11:41:33 ON 07 JUN 2010
L2 76 S L1
L3 54 S L2 AND (CANCER OR TUMOR OR NEOPLASM)
L4 3 S L3 AND AD<20031107
L5 3 DUP REM L4 (0 DUPLICATES REMOVED)

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.17	40.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

FILE 'MEDLINE' ENTERED AT 11:45:31 ON 07 JUN 2010

FILE 'EMBASE' ENTERED AT 11:45:31 ON 07 JUN 2010

FILE 'BIOSIS' ENTERED AT 11:45:31 ON 07 JUN 2010

=> s l1 or l1<chem>

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.33	43.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

```
CA SUBSCRIBER PRICE                                          0.00      -2.55

FILE 'REGISTRY' ENTERED AT 11:45:39 ON 07 JUN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1- CHEM
L6          SEL L1 1- CHEM :       9 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      15.49      59.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)           SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -2.55

FILE 'MEDLINE' ENTERED AT 11:45:40 ON 07 JUN 2010

FILE 'EMBASE' ENTERED AT 11:45:40 ON 07 JUN 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:45:40 ON 07 JUN 2010
Copyright (c) 2010 The Thomson Corporation

S L1 OR L6


L8         126 L1 OR L7

=> s l8 and pd<20031107
   1 FILES SEARCHED...
L9             5 L8 AND PD<20031107

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10            5 DUP REM L9 (0 DUPLICATES REMOVED)

=> d l10 1-5 ibib abs

L10  ANSWER 1 OF 5  EMBASE  COPYRIGHT (c) 2010 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:   2003373828  EMBASE
TITLE:              Anti-cancer drug discovery and development summit.
AUTHOR:             Blakey, David C. (correspondence)
CORPORATE SOURCE:   AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10
                    4TF, United Kingdom. david.blakey@astrazeneca.com
SOURCE:             Expert Opinion on Investigational Drugs, (1 Sep
                    2003) Vol. 12, No. 9, pp. 1577-1582.
                    Refs: 15
                    ISSN: 1354-3784  CODEN: EOIDER
COUNTRY:            United Kingdom
DOCUMENT TYPE:      Journal; Conference Article; (Conference paper)
FILE SEGMENT:       016     Cancer
```

030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 2 Oct 2003
Last Updated on STN: 2 Oct 2003

AB The 5th Annual Anti-Cancer Drug Discovery and Development Summit brought together an international group of academic and industry scientists to discuss recent therapeutic developments in the field of oncology. The focus of the meeting was novel targeted approaches, i.e., those agents directed against targets that are overexpressed or overactive in tumour cells. It was acknowledged that cytotoxic agents will continue to play a key role in the treatment of cancer and new developments in this area were also discussed. With over 400 anticancer drugs in clinical development and a number of recent registrations, there is great optimism that significant therapeutic advances can be made.

L10 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:501918 BIOSIS
DOCUMENT NUMBER: PREV200300498316
TITLE: Preclinical pharmacokinetics and metabolism of CHIR258, a potent tyrosine kinase inhibitor.
AUTHOR(S): Vora, Jayesh [Reprint Author]; Haroldsen, Peter [Reprint Author]; Renhowe, Paul [Reprint Author]; Heise, Carla [Reprint Author]; Steigerwalt, Ronald [Reprint Author]; Todd, Marque [Reprint Author]; Harris, Alex [Reprint Author]; Samara, Emil [Reprint Author]
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 753. print.
Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Oct 2003
Last Updated on STN: 29 Oct 2003

L10 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003363876 EMBASE
TITLE: American Association for Cancer Research - 9th Annual Meeting: Investigating drugs: 11-14 July 2003, Washington, DC, USA.
AUTHOR: Mackay, Janie (correspondence); Williams, Laura
CORPORATE SOURCE: Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, United Kingdom. laura.williams@current-drugs.com; janie.mackay@current-drugs.com
SOURCE: IDrugs, (1 Aug 2003) Vol. 6, No. 8, pp. 736-738.
ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
052 Toxicology

LANGUAGE: English
ENTRY DATE: Entered STN: 25 Sep 2003
Last Updated on STN: 25 Sep 2003

L10 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003481481 EMBASE
TITLE: The impact of anti-angiogenic agents on cancer therapy.
AUTHOR: Marme, Dieter (correspondence)
CORPORATE SOURCE: Tumor Biology Center, Institute of Molecular Oncology, Breisacherstrasse 117, 79106 Freiburg, Germany. marme@tumorbio.uni-freiburg.de
SOURCE: Journal of Cancer Research and Clinical Oncology, (Nov 2003) Vol. 129, No. 11, pp. 607-620.
Refs: 89
ISSN: 0171-5216 CODEN: JCROD7
COUNTRY: Germany
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Dec 2003
Last Updated on STN: 29 Dec 2003

L10 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003276961 EMBASE
TITLE: Kinases - SMi Conference 9-10 April 2003, London, UK.
AUTHOR: Harrison, Ruth (correspondence)
CORPORATE SOURCE: Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4LB, United Kingdom. ruth.harrison@current-drugs.com
SOURCE: IDrugs, (1 Jun 2003) Vol. 6, No. 6, pp. 560-562.
ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 24 Jul 2003
Last Updated on STN: 24 Jul 2003
AB Dr. Moss briefly summed up the conference by describing the growth in the development of kinase research over the years and the commitment being invested by companies aiming to find effective screening strategies. He closed the day by remarking on the new challenge for researchers of turning the concepts discussed into successful drugs.

=> d his

(FILE 'HOME' ENTERED AT 11:40:40 ON 07 JUN 2010)

FILE 'REGISTRY' ENTERED AT 11:41:12 ON 07 JUN 2010
L1 2 S DOVITINIB

FILE 'CAPLUS' ENTERED AT 11:41:33 ON 07 JUN 2010
L2 76 S L1

```
L3            54 S L2 AND (CANCER OR TUMOR OR NEOPLASM)
L4             3 S L3 AND AD<20031107
L5             3 DUP REM L4 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:45:31 ON 07 JUN 2010

     FILE 'REGISTRY' ENTERED AT 11:45:39 ON 07 JUN 2010
                SET SMARTSELECT ON
L6           SEL L1 1- CHEM :       9 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:45:40 ON 07 JUN 2010
L7           126 S L6
L8           126 S L1 OR L7
L9             5 S L8 AND PD<20031107
L10            5 DUP REM L9 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    22.50      81.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -2.55

STN INTERNATIONAL LOGOFF AT 11:47:31 ON 07 JUN 2010
```